

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUA MEDICINE

華領醫藥

(Incorporated in the Cayman Islands with limited liability)

(stock code: 2552)

CHANGE IN COMPOSITION OF THE REMUNERATION COMMITTEE

The board of directors (the “**Board**”) of Hua Medicine (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that, Mr. Yiu Leung Andy CHEUNG (“Mr. Cheung”), the independent non-executive Director, has been appointed as a member of the Remuneration Committee with effect from November 27, 2025. Mr. Cheung’s other positions on the Board remain unchanged.

Biographical details of Mr. Cheung and other information which is required to be disclosed under the Listing Rules were set out in the 2024 annual report of the Company. As at the date of this announcement, there has been no change in such information save as disclosed in this announcement.

Following the above changes, the Remuneration Committee will comprise three members, namely Mr. William Robert Keller (chairman of the Remuneration Committee), Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung.

The Board would like to take this opportunity to extend its warm welcome to Mr. Cheung in his new role in the Remuneration Committee.

By Order of the Board
Dr. Li Chen
*Chief Executive Officer and
Executive Director*

Hong Kong, November 27, 2025

As at the date of this announcement, the Board comprises Dr. Li Chen, Mr. George Chien Cheng Lin and Dr. Yi Zhang as executive Directors; Mr. Robert Taylor Nelsen as non-executive Director; and Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung as independent non-executive Directors.